Last updated: September 15, 2026
Pulmicort Respules is AstraZeneca's nebulized budesonide inhalation suspension for maintenance treatment of asthma in young children. The product has moved from protected branded medicine to a mature, genericized respiratory product. Its commercial value remains supported by pediatric use, established clinical familiarity, and demand in markets where nebulization is preferred, but long-term growth is constrained by generic budesonide, competing inhaled corticosteroids, and the absence of meaningful new indications.
AstraZeneca reports Pulmicort sales at the brand or franchise level rather than separating Respules from other Pulmicort presentations in all public filings. The available financial record therefore supports an assessment of the Pulmicort franchise, not a precise Respules-only revenue calculation.[1-5]
What is Pulmicort Respules and how is it used?
Pulmicort Respules contains budesonide, an inhaled corticosteroid administered through a jet nebulizer. The U.S. product is approved for the maintenance treatment of asthma in children 12 months to 8 years of age.[6]
The product is supplied as single-use unit-dose ampules in strengths that include:
| Strength |
Typical product description |
| 0.25 mg/2 mL |
Lower-dose pediatric nebulized suspension |
| 0.5 mg/2 mL |
Intermediate-dose presentation |
| 1 mg/2 mL |
Higher-dose presentation |
Pulmicort Respules is a controller medicine. It is not intended for rapid relief of acute bronchospasm. The product's commercial position is strongest among young children who cannot reliably use a metered-dose inhaler with a spacer or a dry-powder inhaler.[6]
Which patient segments support demand?
Demand is concentrated in:
- Children with persistent asthma requiring daily inhaled corticosteroid therapy.
- Patients who depend on nebulizer administration.
- Pediatric practices and caregivers familiar with unit-dose nebulized treatment.
- Healthcare systems where budesonide nebulization is included in treatment protocols.
- Emerging markets with relatively high use of nebulizers and lower penetration of newer inhaler platforms.
Pulmicort Respules has a narrower addressable population than broad adult respiratory brands such as Symbicort, Breztri Aerosphere, or Trelegy Ellipta. Its pediatric focus protects a specialized niche but limits future volume expansion.
How has Pulmicort's financial trajectory developed?
Pulmicort is a mature respiratory franchise with a substantially different trajectory from AstraZeneca's growth products. The product has generated durable revenue after loss of core exclusivity, but its commercial profile is defined by volume retention and geographic resilience rather than premium pricing or rapid prescription growth.
AstraZeneca's annual reports identify Pulmicort as a respiratory product but do not consistently provide a separate Respules revenue line. Reported Pulmicort performance has generally reflected three factors:
- Generic price pressure in the United States and other developed markets.
- Continued demand in China and international markets.
- Stable clinical use in pediatric asthma despite limited innovation in the product itself.
What are the main financial drivers?
| Driver |
Effect on Pulmicort Respules |
| Generic budesonide inhalation suspension |
Reduces price and branded volume |
| Pediatric asthma prevalence |
Supports recurring baseline demand |
| Nebulizer dependence |
Preserves a differentiated delivery niche |
| China and emerging markets |
Can offset mature-market erosion |
| Reimbursement policy |
Determines substitution and net pricing |
| Unit-dose packaging |
Adds manufacturing and packaging cost |
| Limited new indications |
Restricts growth potential |
| AstraZeneca commercial scale |
Supports distribution and formulary access |
The financial trajectory is best characterized as mature and defensive. Pulmicort can remain commercially material because asthma is chronic and because some pediatric patients continue to require nebulized administration. The product does not have the growth characteristics of a recently launched biologic or combination inhaler.
Does AstraZeneca disclose Respules-only revenue?
No. Public AstraZeneca reporting generally aggregates Pulmicort sales across the brand or product family. The reported figures cannot be used as a precise measure of Pulmicort Respules revenue without product-level geographic and presentation data.
This distinction matters in valuation. A Pulmicort franchise figure may include other budesonide presentations, regional formulations, or sales outside the U.S. The economic value of Respules alone is therefore lower than the total Pulmicort figure reported by AstraZeneca.[1-5]
When did Pulmicort Respules lose exclusivity?
Pulmicort Respules lost effective U.S. product exclusivity before the current market period. AstraZeneca's original protection covered budesonide inhalation suspension and related formulation or use claims, but generic competition has been established in the U.S. market.
Teva announced the U.S. launch of a generic version of Pulmicort Respules in 2019. The launch materially changed the product's economics by introducing an FDA-approved generic equivalent to the reference inhalation suspension.[7]
The practical exclusivity timeline is:
| Period |
Market status |
| 2000 |
FDA approval of Pulmicort Respules in the U.S. |
| 2000s |
Branded pediatric nebulized corticosteroid with patent protection |
| 2010s |
Patent and regulatory challenges intensify |
| 2019 |
Teva launches a generic budesonide inhalation suspension in the U.S. |
| 2020s |
Mature branded product with generic substitution and regional price pressure |
The commercial loss of exclusivity did not eliminate branded demand. Physicians may continue prescribing Pulmicort because of familiarity, historical use, formulary positioning, and caregiver acceptance. The launch did, however, reduce the brand's ability to maintain premium pricing.
What patents protect Pulmicort Respules?
Pulmicort Respules was protected by patents covering budesonide inhalation suspension formulations, pharmaceutical compositions, and related methods of treatment. The core commercial protection has expired or is no longer sufficient to block approved generic competition in the United States.
The principal patent categories were:
- Budesonide inhalation suspension formulations.
- Particle-size and suspension characteristics.
- Pharmaceutical compositions for nebulized delivery.
- Methods of treating asthma with inhaled budesonide.
- Manufacturing and formulation processes.
A historical patent often associated with the product is U.S. Patent No. 6,598,603, which concerned budesonide inhalation suspension technology. Patent term, pediatric extensions, terminal disclaimers, and the scope of listed claims must be evaluated against the specific Orange Book entry and relevant FDA patent records.[8]
What is the Orange Book status of Pulmicort Respules?
FDA's Orange Book identifies approved reference-listed-drug and generic relationships for budesonide inhalation suspension. The relevant regulatory issue is not merely whether an old patent remains listed. The decisive question is whether an unexpired listed claim blocks approval or launch of an ANDA applicant.
For Pulmicort Respules, the existence of approved generic products demonstrates that the principal regulatory barrier to U.S. substitution has been overcome. Any remaining patents would need to be assessed claim by claim for enforceability, scope, and applicability to the specific strength and dosage form.[8]
Which companies challenge or compete with Pulmicort Respules?
The competitive field includes generic budesonide manufacturers, branded inhaled corticosteroid suppliers, and alternative delivery systems.
| Competitor category |
Examples |
Competitive effect |
| Generic budesonide inhalation suspension |
Teva and other ANDA-approved suppliers |
Direct price and substitution pressure |
| Nebulized corticosteroids |
Budesonide products in international markets |
Erodes brand differentiation |
| Fluticasone products |
Flovent and generic fluticasone presentations |
Competes for inhaled corticosteroid prescriptions |
| Metered-dose inhalers |
Fluticasone, beclomethasone and related products |
Alternative delivery for older or capable children |
| Dry-powder inhalers |
Age-appropriate inhaled corticosteroid products |
Limits demand as children mature |
| Combination inhalers |
ICS/LABA products for appropriate patients |
Competes outside the youngest pediatric segment |
The most direct competitor is generic budesonide inhalation suspension. Other inhaled corticosteroids are less direct substitutes because age, device technique, dose equivalence, labeling, and payer policy affect interchangeability.
How strong is the Pulmicort patent estate?
The current patent estate is commercially weak in the United States compared with the estate that supported the original brand launch. Generic entry has already occurred, and the core value of the product now rests on regulatory approval, clinical familiarity, manufacturing capability, supply reliability, and market access.
Patent strength differs by jurisdiction:
| Jurisdiction |
Current commercial assessment |
| United States |
Core product protection has been overcome by generic approval |
| European Union |
Country-specific patent and SPC history; generic exposure varies by market |
| China |
Local patent status, procurement rules, and centralized purchasing are material |
| Japan |
Mature respiratory market with local approval and reimbursement considerations |
| Emerging markets |
Patent barriers may be weaker, but regulatory and distribution barriers remain |
The strongest remaining barriers are not necessarily patent barriers. They include sterile suspension manufacturing, container-closure integrity, dose uniformity, stability, nebulizer compatibility, regulatory documentation, and reliable supply of unit-dose ampules.
What manufacturing and regulatory barriers remain?
Budesonide inhalation suspension is more difficult to manufacture than a conventional oral solid. A competitor must control:
- Uniform drug dispersion in suspension.
- Particle-size distribution.
- Dose consistency across ampules.
- Microbial quality and preservative characteristics.
- Container compatibility and extractables.
- Stability through shelf life.
- Compatibility with approved nebulizer systems.
- Packaging and filling of sterile or controlled-quality unit doses.
These requirements can limit the number of reliable suppliers even after patent expiry. The result is a market with generic competition but potentially fewer durable manufacturers than a standard tablet market.
FDA approval requires an ANDA applicant to demonstrate pharmaceutical equivalence and bioequivalence through the applicable regulatory pathway. Inhalation products can face more complex equivalence questions than oral medicines because device performance and delivered dose affect clinical exposure.[9]
What Paragraph IV challenges affected Pulmicort Respules?
Generic applicants typically use Paragraph IV certifications when they assert that relevant patents are invalid, unenforceable, or not infringed. Pulmicort Respules faced the standard Hatch-Waxman challenge pathway associated with generic entry.
The key commercial outcome is more important than the procedural history: an approved generic entered the U.S. market, showing that patent litigation and regulatory review did not preserve effective U.S. exclusivity for the branded product through the 2020s.
Paragraph IV risk remains relevant to any later reformulation or device-specific product. A new presentation could create a separate patent and litigation profile, but the established budesonide suspension has limited ability to recreate the original exclusivity position.
What litigation and settlement issues affect Pulmicort Respules?
The principal legal issues have involved:
- Validity of formulation patents.
- Infringement by generic budesonide suspensions.
- Whether listed claims cover the ANDA product.
- Regulatory exclusivity and approval timing.
- Potential settlements governing generic launch dates.
Settlement terms are not always fully public, and a settlement may govern a specific applicant without creating a market-wide launch date. The presence of an approved generic indicates that any prior litigation did not preserve a complete long-term market block.
For current diligence, the relevant legal questions are:
- Whether a patent remains listed for the exact strength and dosage form.
- Whether the patent has an enforceable term in the target jurisdiction.
- Whether an ANDA applicant has received tentative or final approval.
- Whether the generic is commercially available or only technically approved.
- Whether supply agreements or authorized-generic arrangements affect net pricing.
What is the FDA regulatory status of Pulmicort Respules?
Pulmicort Respules is an FDA-approved inhaled corticosteroid for pediatric asthma maintenance therapy. Its regulatory value comes from an established reference product and a long safety and clinical-use record.[6]
The generic market is regulated through ANDAs referencing the branded product. FDA approval of a generic does not require the generic to reproduce AstraZeneca's brand, but it must meet applicable equivalence and quality requirements.
The product's regulatory position is stable, but its growth potential is limited because:
- The core indication is established.
- The patient population is narrowly defined.
- Generic approval enables substitution.
- The product is not a new chemical entity.
- No major label expansion has changed its addressable market.
What licensing deals support Pulmicort Respules?
Pulmicort originated from AstraZeneca's respiratory portfolio, and the brand has been commercialized primarily through AstraZeneca's own global infrastructure. Public disclosures do not identify a recent licensing transaction that materially changes the ownership or economics of Pulmicort Respules.
Regional commercialization, distribution, and generic supply agreements can affect local revenue without changing global ownership of the brand. Such arrangements should be distinguished from a patent license or acquisition of the product's core rights.
What generic launch scenarios exist?
Scenario 1: Continued generic erosion
This is the base case. Multiple suppliers or stronger payer substitution reduce branded volume and net price. AstraZeneca retains residual prescriptions among physicians and caregivers who prefer the branded product.
Scenario 2: Stable branded niche
Pulmicort Respules remains resilient in pediatric and nebulizer-dependent patients. Generic penetration grows, but supply constraints or limited competition preserve a branded segment.
Scenario 3: Procurement-driven price compression
Government tenders and centralized purchasing accelerate substitution, especially in China and other price-sensitive markets. Volume may remain stable while revenue declines.
Scenario 4: Supply disruption
Manufacturing or quality problems at one or more generic suppliers could temporarily restore branded demand. This would be a temporary volume benefit, not a restoration of exclusivity.
How does Pulmicort Respules compare with competing respiratory assets?
| Factor |
Pulmicort Respules |
Newer branded inhalers |
Respiratory biologics |
| Patient population |
Primarily young children with asthma |
Broader age range |
Severe disease subgroups |
| Delivery |
Jet nebulizer |
Inhaler or device-based |
Injection |
| Patent strength |
Mature and largely overcome |
Often active |
Often strong and layered |
| Pricing power |
Low to moderate |
Moderate to high |
High |
| Generic risk |
High |
Varies |
Biosimilar risk, usually later |
| Growth profile |
Mature or declining |
Potentially growing |
Growth-oriented |
| Manufacturing complexity |
Suspension and unit-dose filling |
Device and formulation complexity |
Biologic production |
| Main commercial defense |
Clinical familiarity and supply |
Innovation and device differentiation |
Clinical outcomes and unmet need |
Pulmicort has a lower risk profile than a newly launched product because its demand base is established. It also has lower upside because patent protection and premium pricing have eroded.
What revenue exposure does AstraZeneca face?
Pulmicort is unlikely to represent a major concentration risk for AstraZeneca's overall revenue base. AstraZeneca's financial profile is dominated by oncology, rare disease, cardiovascular, renal and metabolic products, and newer respiratory medicines. Pulmicort remains relevant as a cash-generating mature brand but is not a primary driver of corporate growth.[1-5]
The main exposure is erosion of a durable legacy revenue stream rather than a sudden loss of a flagship product. The financial impact of further generic penetration depends on:
- The proportion of Pulmicort sales generated by Respules.
- Geographic mix.
- Generic substitution rates.
- AstraZeneca's branded net price.
- Procurement and reimbursement reforms.
- Supply reliability among generic competitors.
Key Takeaways
- Pulmicort Respules is a mature budesonide inhalation suspension for pediatric asthma maintenance therapy.
- AstraZeneca does not consistently disclose Respules-only revenue, so Pulmicort franchise sales should not be treated as a direct Respules valuation.
- U.S. generic competition was established by 2019, materially reducing branded pricing power.
- The core patent estate is no longer an effective U.S. barrier to generic entry.
- Remaining commercial defenses are clinical familiarity, pediatric specialization, nebulizer dependence, supply reliability, and international market access.
- Manufacturing complexity limits the market to qualified suppliers but does not restore meaningful exclusivity.
- The financial trajectory is mature and defensive, with likely continued price and volume pressure in markets with high generic substitution.
- The greatest long-term risk is procurement-driven commoditization, particularly where budesonide inhalation suspension is subject to tender pricing.
FAQs
Is Pulmicort Respules still under patent?
Core U.S. product protection has been overcome by generic entry. Specific formulation or jurisdictional patents require separate review against the applicable Orange Book or national patent records.
Is generic budesonide inhalation suspension equivalent to Pulmicort Respules?
FDA-approved generic budesonide inhalation suspensions reference Pulmicort Respules and must meet applicable pharmaceutical equivalence and approval requirements. Device and administration instructions remain important to product performance.
Can Pulmicort Respules be substituted automatically?
Substitution depends on state law, payer rules, pharmacy policy, and the regulatory status of the specific generic product. FDA therapeutic-equivalence ratings and local substitution rules determine the practical result.
Does Pulmicort Respules have biosimilar risk?
No. Budesonide is a small-molecule corticosteroid, not a biologic. Its competitive risk is generic substitution under the ANDA pathway, not biosimilar competition.
What would increase the commercial value of Pulmicort Respules?
A sustained pediatric nebulizer preference, generic supply disruption, favorable reimbursement, or growth in international markets could support revenue. A new formulation or delivery system would need distinct regulatory and patent protection to create material incremental value.
References
- AstraZeneca. (2020). Annual report and Form 20-F 2019.
- AstraZeneca. (2021). Annual report and Form 20-F 2020.
- AstraZeneca. (2022). Annual report and Form 20-F 2021.
- AstraZeneca. (2023). Annual report and Form 20-F 2022.
- AstraZeneca. (2024). Annual report and Form 20-F 2023.
- U.S. Food and Drug Administration. (2024). Pulmicort Respules: Prescribing information.
- Teva Pharmaceuticals. (2019). Teva launches first generic version of Pulmicort Respules in the United States.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2013). Draft guidance on budesonide inhalation suspension.
